Please login to the form below

Not currently logged in
Email:
Password:

Almirall launches Solaraze in Spain

Pharma company says move strengthens its dermatology business strategy

Almirall has launched its actinic keratosis treatment Solaraze (diclofenac sodium and hyaluronic acid) in Spain.

Barcelona-based Almirall said the domestic launch of Solaraze consolidates its business strategy in dermatology, which along with respiratory R&D makes up the firm's key research focus.

Through a gel formulation applied twice a day for 90 days Solaraze stimulates the skin's defence system to destroy damaged cells and encourage healthy cells to replace them.

Actinic keratosis is a pre-cancerous lesion that an estimated one in six people will develop at some point in their lives.

Also known as solar keratosis, actinic keratosis appears as a small scaly or rough bump on the skin's surface. It takes years to develop and usually appears on the face, ears or scalp, the neck and back of hands and forearms and on the lips.

The lesions, which are most often caused by exposure to the sun, are not usually life-threatening if they are detected and treated in the early stages.

Solarze was developed by SkyePharma and first marketed by Shire Pharmaceuticals, until Almirall acquired the product, and seven others, in a $213m deal in 2007.

15th December 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics